Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Complete Genome Sequence of the Cluster DJ Actinobacteriophage, Petito, isolated on the host Gordonia rubripertinca. | MicroPubl Biol | 2025 | 39839714 | PubTator, text mining | PubMed |
| Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas. | Pathobiology | 2025 | 39837304 | PubTator, text mining | PubMed |
| PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates. | Bioconjug Chem | 2025 | 39832173 | PubTator, text mining | PubMed |
| Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. | Chem Rev | 2025 | 39818743 | PubTator, text mining | PubMed |
| OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. | Mol Cancer Ther | 2025 | 39786401 | PubTator, text mining | PubMed |
| Large, recursive membrane platforms are associated to Trop-1, Trop-2, and protein kinase signaling for cell growth. | Mol Biol Cell | 2025 | 39785844 | PubTator, text mining | PubMed |
| Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer. | Nanoscale | 2025 | 39775761 | PubTator, text mining | PubMed |
| Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma. | Clin Lung Cancer | 2025 | 39753485 | PubTator, text mining | PubMed |
| Assessment of targets of antibody drug conjugates in SCLC. | NPJ Precis Oncol | 2025 | 39748112 | PubTator, text mining | PubMed |
| A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan. | Sci Rep | 2025 | 39747638 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy. | Bioorg Med Chem Lett | 2025 | 39732148 | PubTator, text mining | PubMed |
| Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. | Am J Clin Pathol | 2025 | 39705501 | PubTator, text mining | PubMed |
| [Pathology and molecular pathology of carcinoma of the penis]. | Pathologie (Heidelb) | 2025 | 39694900 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study. | Clin Cancer Res | 2025 | 39665770 | PubTator, text mining | PubMed |
| The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat? | Cancer Res Treat | 2025 | 39608345 | PubTator, text mining | PubMed |
| Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. | Clin Cancer Res | 2025 | 39585341 | PubTator, text mining | PubMed |
| An EpCAM/Trop2 mechanostat differentially regulates collective behaviour of human carcinoma cells. | EMBO J | 2025 | 39572744 | PubTator, text mining | PubMed |
| Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer. | Mol Cancer Ther | 2025 | 39564769 | PubTator, text mining | PubMed |
| Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. | Clin Pharmacol Ther | 2025 | 39543869 | PubTator, text mining | PubMed |
| Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. | Clin Cancer Res | 2025 | 39513959 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=33